Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials (Q38181898)

30 August 2017

0 references

Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials (English)

1 reference

chemotherapy-induced acral erythema

30 August 2017

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Lígia Traldi Macedo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

Joao Paulo Nogueira Lima

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

Lucas Vieira dos Santos

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

publication date

26 January 2014

1 reference

Supportive Care in Cancer

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1585-1593

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24463616 AND SRC:MED&resulttype=core&format=json

Unilateral Hand-Foot Syndrome: Does It Take Sides? Case Report and Literature Review

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

The cutaneous histopathology of chemotherapeutic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Management of hand-foot syndrome induced by capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00520-014-2129-Z

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

21 January 2018

1 reference

12 December 2020

The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia

1 reference

12 December 2020

The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

1 reference

12 December 2020

Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.

1 reference

12 December 2020

The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study

1 reference

12 December 2020